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The search for novel therapies for the treatment of Alzheimer’s disease is an 
urgent need, due to the current paucity of available pharmacological tools and 
the recent failures obtained in clinical trials. Among other strategies, the 
modulation of amyloid-triggered neuroinflammation by the endocannabinoid 
system seems of relevance. Previous data indicate that the enhancement of the 
endocannabinoid tone through the inhibition of the enzymes responsible for the 
degradation of their main endogenous ligands may render beneficial effects. 
Based on previously reported data, in which we described a paradoxical effect 
of the genetic deletion of the fatty acid amide hydrolase, we here aimed to 
expand our knowledge on the role of the endocannabinoid system in the 
context of Alzheimer’s disease. To that end, we inhibited the production of 
interleukin-1, one of the main inflammatory cytokines involved in the 
neuroinflammation triggered by amyloid peptides, in a transgenic mouse model 
of this disease by using minocycline, a drug known to impair the synthesis of 
this cytokine. Our data suggest that interleukin-1 may be instrumental in order 
to achieve the beneficial effects derived of fatty acid amide hydrolase genetic 
inactivation. This could be appreciated at the molecular (cytokine expression, 
amyloid production, plaque deposition) as well as behavioral levels (memory 
impairment). We here describe a previously unknown link between the 
endocannabinoid system and interleukin-1 in the context of Alzheimer’s 










The role of neuroinflammation in Alzheimer’s disease (AD) is a subject of 
intense debate and analysis. The classical view dictates that the appearance of 
beta amyloid (A) oligomers and the formation of amyloid-enriched neuritic 
plaques in the brain parenchyma trigger a myriad of deleterious effects and, 
among them, a powerful inflammatory response in which glial cells (and, 
remarkably, microglia) play a crucial role by secreting cytokines, activating 
membrane hemichannels, phagocytosing amyloid and cell debris, etc [1]. As 
this inflammatory process extends in time, the neuronal damage in surrounding 
areas gets increased and inflammation perpetuates the process [2]. In this 
context, the use of antiinflammatory drugs has been postulated, but clinical and 
preclinical data have not been conclusive so far [3]. 
 
Under this conceptual paradigm, the activation of neuroprotective endogenous 
mechanisms, such as the endocannabinoid system (ECS), seems of great 
interest. The ECS is comprised of receptors, endogenous ligands and synthetic 
and degradative enzymes that has been shown to provide neuroprotection 
under different types of brain insult [4]. Among other possible approaches, the 
enhancement of the EC tone through the inhibition of the main degrading 
enzymes for these endogenous ligands is presently considered a promising 
approach in AD, as several recent studies have shown the beneficial effects 
derived of the genetic or pharmacological inhibition of monoacylglycerol lipase 
(MAGL, the main degradative enzyme for 2-arachidonoylglycerol) or fatty acid 
amide hydrolase (FAAH, for N-arachidonoylethanolamine, AEA) [5–7].  
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Regarding FAAH, we recently reported that its genetic inactivation led to a pro-
inflammatory phenotype in the context of AD, both in vitro as well as in vivo 
[7,8]. Astrocytes in primary culture obtained from neonatal FAAH-/- mice 
exhibited an enhanced secretion of inflammatory cytokines (IL1, IL6, CCL-2, 
etc) that was accompanied by an increased expression of COX-2, iNOS or 
TNF when exposed to the pathological form of the beta amyloid peptide. 
Further, several signaling cascades known to be directly involved in amyloid-
triggered neuroinflammation (p38 MAPK, ERK 1/2 and NFkB) were also proved 
to be earlier, and more intensely, activated in FAAH-/- than in WT astrocytes 
after exposure to A. Interstingly, this exacerbated pro-inflammatory response 
was only evident in FAAH-lacking astrocytes, but not present when this enzyme 
was subjected to pharmacological inhibition with the well-described irreversible 
inhibitor, URB597 [8].   
 
These data were subsequently confirmed and expanded by using an animal 
model of AD [7]. Thus, samples from cortices and hippocampi of 5xFAD/FAAH-/- 
brains showed increased mRNA levels of several key cytokines (IL1, IL6, and 
TNF) that were associated to a significant decrease in APP, in amyloid-
enriched neuritic plaques as well as in A1-40 and A1-42 levels. Finally, this 
enhanced inflammatory milieu was paradoxically accompanied by decreased 
astro- and micro-gliosis and by an improved memory-related behavioral 
performance. Altogether, these data led us to conclude that FAAH gene 
deletion had a profound effect in the cerebral inflammatory status in the context 
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of AD, involving several cytokines known to play a critical role in this disease, 
including IL1 [7]. 
 
IL1 is a cytosolic cytokine with pleiotropic functions in the brain, including 
neuronal proliferation, differentiation, apoptosis, and long-term potentiation [9]. 
The canonical synthetic route for this cytokine shows that it is synthesized in a 
precursor, biologically inactive form (pro-IL1) that will be subsequently cleaved 
by an intracellular enzyme (IL1-converting enzyme, also identified as caspase-
1) to generate the mature, fully active peptide [10]. The mechanisms controlling 
the release of IL1 from cells in the CNS are still a matter of controversy, 
ranging from plasma membrane translocation, exosomes or other forms of 
secretory microvesicles, and being microglia the main source of this cytokine in 
the context of neuroinflammation [9][11]. Importantly, previous in vitro reports 
pointed out to a direct interaction between the ECS and the IL1 signaling 
pathways in the control of cell damage [12] and, more recently, neurogenesis 
[13]. 
 
The present study was designed to deeper explore the exacerbated 
inflammatory phenotype observed in the absence of FAAH as well as the 
interplay between the ECS and IL1 in the context of A-induced 
neuroinflammation. To that end, we used minocycline to impair IL1 synthesis 
in a mouse model of AD and analyzed the molecular changes that could 




2. MATERIALS AND METHODS 
 
2.1. Mice and minocycline treatments 
Mice used in these studies were described in our previous study [7] and were 
housed and bred in the animal facilities of Universidad Rey Juan Carlos 
(Alcorcón, Madrid, Spain). Experimental protocols met the European and 
Spanish regulations for protection of experimental animals (86/609/EEC and RD 
1201/2005 and 53/2013). 6-month old WT and 5xFAD mice (B6SJL-Tg 
(APPSwFlLon,PSEN1*M146L*L286V) 6799Vas/ Mmjax; Jackson Laboratories; 
Bar Harbor, ME, USA; [14]) were used for the present studies. 5xFAD mice 
overexpress the human APP gene with 3 Familiar Alzheimer’s Disease (FAD) 
mutations, as well as the human PS1 gene containing two FAD mutations, both 
of them under the control of mouse Thy1 promoter. 5xFAD mice were 
backcrossed with FAAH-/- mice (which have replaced the first FAAH exon; [15]) 
for at least 10 generations, so that to obtain the 5xFAD/FAAH-/- counterparts. 
Mice of each genotype were sub-divided in two groups: 5xFAD and 
5xFAD/FAAH-/- vehicle (veh), treated with NaCl 0,9%, and 5xFAD and 
5xFAD/FAAH-/- minocycline (mino), treated with 10mg/kg/day of minocycline 
hydrochloride (Sigma Aldrich, St Louis, MO, USA), as described by [16]. The 
experimental protocol consisted of injecting intraperitoneally either the drug or 
the vehicle once a day during 12 consecutively days. Two hours after the last 
dose, mice were sacrificed by cervical dislocation, and brains were quickly 
removed, and divided in hemispheres: one of them was embedded in paraffin 
for staining, and the other one was frozen in isopentane, and stored at -80oC.  
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The procedure followed to prepare the minocycline solution comprise the 
reconstitution of the minocycline hydrochloride in NaCl 0,9% at a concentration 
of 1,5 mg/mL, and the resulted fresh solution was later adjusted at a pH of 7.4, 
and stored at -80oC until use. Minocycline-treated mice received a dose of 200 
µL per 30g weight, while vehicle animals were treated with the corresponding 
volume of NaCl 0,9%. Weight of animals was measured every day in order to 
inject the correct volume and dose, and for the detection of any symptom of 
toxicity [17]. 
 
2.2. Behavioral determinations 
Memory performance was evaluated as described in our previous work [7] and 
based on the Morris water maze test (MWM) method described by Vorhees and 
Williams [18]. On day 8 of treatment with minocycline or vehicle (N=9-11 per 
group), spatial memory acquisition was tested for four consecutive days, four 
trials per day. Mice were released into opaque water facing the tank wall 
starting from different positions each day and were allowed to swim for a 
maximum of 60 seconds in order to reach a hidden platform. The parameter 
analysed in the present experiments was the time spent in finding the hidden 
platform (escape latency). Data were analysed by using the Smart 3.0 software 
(Panlab, Barcelona, Spain). 
 
2.3. Isolation of microglial cells and flow cytometry 
To facilitate the separation of microglia, brains were dissected and 
enzymatically digested. Then, the resulting suspension was mechanically 
dissociated and filtered through a 70-μm cell strainer. Cells were incubated 
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immediately with CD11b MicroBeads and were separated in a magnetic field 
using MACS Column (Miltenyi Biotec, Madrid, Spain). Both CD11b-negative 
and CD11b-positive effluent fractions were collected for further characterization. 
Additionally, cells were stained with CD11bPE (Miltenyi), CD45-APCVio770 
(Miltenyi), CD16/32-PerCP-Cy5.5 and CD206-APC (both from Invitrogen, 
Carlsbad, CA, USA) antibodies. Samples were read on a MACSQuant Flow 
Cytometer and analysed with MACS Quantify (Miltenyi Biotec). 
 
Fluorescence spillover compensation values were generated using pooled 
unseparated/enriched cell preparations rather than commercially available 
beads to account for the high autofluorescence of myeloid cells. Debris and 
aggregates were eliminated from the analysis by forward and side scatter 
characteristics, then microglia was identified as CD11b+ CD45lo. Polarization 
states of CD11b+CD45lo microglia were evaluated by expression of the M1 
marker CD16/32 and the M2 marker CD206 with gates established by 
fluorescence minus one (FMO) controls. For each hemisphere, approximately 
ten thousand CD11b+ singlets were analyzed. 
 
 
2.4. mRNA isolation and RT-qPCR  
One frozen hemisphere of each minocycline and vehicle-treated animal was 
dissected so that to recover the cortex and hippocampus areas. Then, Tripure 
Isolation Reagent (Roche Diagnostics, Manheim, Germany) was used so as to 
isolate total RNA for further qPCRs assays. After RNA isolation, its quality was 
ensured by a 1% agarose gel electrophoresis, while its quantity was measured 
by spectrophotometry at 260 nm. Single-strand complementary DNA (cDNA) 
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was synthesized from 1 µg of total RNA with the Transcriptor First Strand cDNA 
Synthesis Kit (Roche). The amount of expression of the different genes and 
cytokines of interest was quantified by qPCR assays in a LightCycler® 480 
Instrument II (Roche). PCR primers and TaqMan probes for TNFα and COX2 
were designed by Tib Molbiol (Berlin, Germany), and were all employed at 0.5 
µM. IL1r and IL1ra were analysed by using a RealTime ready Single Assays 
(assay IDs: 312175 and 318527, correspondingly, Roche), while IL1β, IL10 and 
IL4 were quantified by employing Predesigned qPCR Assays (assay IDs: 
Mm.PT.58.42962427, Mm.PT.58.13531087 and Mm.58.7882098, respectively, 
IDT®, Coralville, IA, USA). 18S was chosen for normalization. PCR assays 
were performed using LightCycler® TaqMan® Master (Roche) and Quantimix 
Easy Probes Kit (Biotools, Madrid, Spain). All assays, except the corresponding 
to IL10 and IL4, were carry out with 2 µL of cDNA, whereas IL10 and IL4 
assays needed 4 µL. Because of the use of a 96-well plate, the qPCR reaction 
was run in duplicates for each sample, including the positive (a sample known 
for showing high expression of all the genes tested) and negative control (no-
template wells). The transcript amounts were calculated using the second 
derivative maximum mode of LC-software, version 1.5 (Roche), and later 
analysed by the 2-ΔΔCt algorithm, so that to obtain the Relative Quantification 
(RQ) values. Further calculations and statistical analysis were done with these 
RQ values. 
 
2.5. Neuritic plaque quantification  
Paraffin-embedded tissues (N=3-4 per group) were cut in 4m slices and 
transferred to slides coated with Vectabond (Vector Laboratories, Burlingame, 
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CA, USA). Once deparaffined and rehydrated, amyloid aggregates were 
labelled with methoxy-X04 staining, as described [19]. Slides were studied and 
photographed with an upright microscope (Nikon 90i, Nikon, Tokyo, Japan) and 
using a DXM1200F camera. Quantification of the slides was performed with 
Metamorph (Molecular Devices, Sunnyvale, CA, USA) and ImageJ (NIH, 
Baltimore, MD, USA) software. Images were converted to 8-bit grayscale for 
analysis. Next, a threshold value was set (to highlight the signal corresponding 
to stained cells only) and the region of interest outlined by using the polygon 
selection tool (ROI tools). The area occupied by methoxy-X04-labelled plaques, 
was quantified and divided by the total area of the selected region. 
 
2.6. Aβ1-42 quantification by ELISA 
To determine Aβ1-42 levels in brain tissue, hippocampus and cortex were 
homogenized in 10 volumes of ice-cold guanidine buffer (5.0 M 
guanidine·HCl/50 mM Tris·Cl, pH 8.0) containing protease inhibitor cocktail 
(Roche). Protein concentrations were determined by BCA assay (Thermofisher, 
Waltham, MA, USA). Human ELISA kits (Invitrogen) were used according to 
manufacturer’s specifications. Optical signals at 450 nm were read on a Sunrise 
microplate reader (Tecan, Männedorf, Switzerland) and sample concentrations 
were determined by comparison with the respective standard curves.  
 
2.7. IL1 quantification by ELISA 
Brain cortex was homogenized with ice-cold lysis buffer [25 mM Hepes (pH 
7.5), 150 mM NaCl, 1% (vol/vol) IGEPAL CA-630, 10 mM MgCl2, 1 mM EDTA, 
and 2% (vol/vol) glycerol] containing protease inhibitor cocktail (Roche), and 
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clarified by centrifugation at 14,000 g at 4°C for 15 minutes. Protein 
concentrations were determined by BCA assay (Thermofisher). IL1β levels in 
the tissue lysates were measured using the RayBio® Mouse IL-1 beta ELISA kit 
(RayBiotech, Inc., Norcross, GA, USA) following the manufacturer's protocol. 
Optical signals at 450 nm were read on a Sunrise microplate reader (Tecan) 
and sample concentrations were determined by comparison with the respective 
standard curves.  
 
2.8. Statistics 
Results are expressed as mean ± SEM. Statistical analysis were made using 2-
way analysis of variance (ANOVA) with Bonferroni’s post-test for multiple 
comparisons. A p value <0.05 was considered as statistically significant. Data 







3.1. The phenotype associated to FAAH-/- mice is proinflammatory and 
affects microglial cells  
We analyzed the M1/M2 profile of microglial cells in the brains of WT and 
FAAH-lacking mice by flow cytometry (figure 1). As expected, we found a 
significant increase in the M1 to M2 ratio in AD brain samples as compared to 
non-pathological ones, both in WT and FAAH-/- mice. Importantly, there was a 
significant difference in this ratio among 5xFAD vs 5xFAD/FAAH-/- mice (figure 
1A), indicating an exacerbated pro-inflammatory state associated to FAAH gene 
deletion. Surprisingly, this increase in the M1/M2 ratio was also accompanied 
by a significant decrease in the number of microglial cells isolated from samples 
obtained from FAAH-lacking mice, suggestive of decreased microgliosis (figure 
1B). We must then conclude that the absence of FAAH partially prevents the 
microgliosis that is prototypical of amyloid pathology but also triggers an 
imbalance of the microglial phenotype towards an exacerbated pro-
inflammatory state, as revealed by the increased M1 over M2 markers. 
 
In addition, we focused on the pattern of expression of several pro- and anti-
inflammatory cytokines known to play a relevant role in the pathogenesis of AD 
and produced mostly by glial cells, including IL1, TNF, IL10 and IL4 (figure 
2). Our data show that the genetic deletion of FAAH has a differential effect on 
the expression levels of these cytokines, by promoting the expression of pro-
inflammatory cytokines (IL1 and TNF) while inducing a decrease in that of 
anti-inflammatory ones (IL10 and IL4). Thus, as expected, both IL1 and TNF 
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mRNA levels were significantly elevated in the brains of AD mice but were 
further increased in samples from 5xFAD/FAAH-/- mice as compared to 5xFAD 
mice (figure 2A and B). On the other hand, IL10 and IL4 were also increased as 
a consequence of the pathology, but only in 5xFAD, not in 5xFAD/FAAH-/- mice 
(figure 2C and D). IL10 mRNA levels were significantly lower in the absence of 
FAAH as compared to 5xFAD. These data show that the genetic deletion of 
FAAH alters the expression pattern of glial cytokines and promotes 
inflammation. 
 
3.2. IL1 system is altered in FAAH-/- mice and is partiatlly normalized by 
minocycline exposure  
We next studied the status of the IL1 system in the brains of FAAH-lacking 
mice and analyzed the impact of the treatment with the IL1 synthesis inhibitor, 
minocycline. We thus quantified the expression levels of several elements of 
this system, including IL1, IL1r and IL1ra (figure 3). We found that mRNA 
levels of IL1 and IL1r were significantly elevated in brain samples of 
5xFAD/FAAH-/- mice as compared to 5xFAD mice (figure 3A and B), while those 
of the IL1ra showed no difference (figure 3C). Finally, IL1 protein levels were 
not modified by FAAH gene deletion (figure 3D). These data confirm previous 
observations indicating that the genetic deletion of FAAH leads to an 
exacerbated expression of some elements of the IL1 transmission system 
without reflect in protein levels. 
 
In addition, we also measured the impact that the exposure to minocycline, a 
compound known to impair IL1 synthesis, may have on these observations. 
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We found that increased IL1 mRNA levels were normalized after treatment 
with minocycline (figure 3A) while those of IL1r also showed similar levels to 
those observed in 5xFAD mice (figure 3B). IL1ra mRNA levels did not change 
after minocycline treatment (figure 3C). Finally, IL1 protein levels were 
significantly decreased after the treatment, confirming the efficacy of 
minocycline regarding the inhibition of IL1 synthesis (figure 3D). 
 
3.3. Minocycline treatment triggers opposite effects in 5xFAD vs 
5xFAD/FAAH-/- mice 
We also studied the effects of the treatment with minocycline at the behavioral 
and molecular levels in respect to the amyloid pathology. Our data show that, in 
concordance with previous reports, minocycline treatment improved memory in 
5xFAD mice (figure 4A) as showed in the MWM test. In contrast, 5xFAD/FAAH-/- 
mice showed a worsening in memory-related behavior in the same test after 
exposure to minocycline (figure 4A).  
 
In addition, minocycline treatment induced a significant decrease in amyloid 
plaques (figure 4B) in 5xFAD but had the opposite effect on 5xFAD/FAAH-/- 
mice. In addition, cortical and hippocampal soluble A1-42 levels in 5xFAD mice 
were significantly higher in 5xFAD as compared to 5xFAD/FAAH-/- mice and 
remained unchanged under minocycline treatment (figures 4C and D). Finally, 
the same treatment regime led to significant increases in amyloid soluble levels 






The present data confirm previous reports showing that the genetic inactivation 
of FAAH leads to a pro-inflammatory, yet beneficial, state in the context of AD 
and suggesting that IL1 may be instrumental in this phenomenon [7,20]. We 
first confirmed the exacerbated inflammatory status associated to the genetic 
deletion of FAAH in a mouse model of AD (5xFAD mice) by studying: i) the 
phenotypic profile of microglial cells by flow cytometry; and ii) the expression 
levels of pro- and anti-inflammatory cytokines. We then used the highly 
lipophilic derivative of tetracycline, minocycline, to interfere the synthesis of IL1 
and analyzed the effects of this impairment on the effects associated to the 
genetic deletion of FAAH. The present results confirm that the blockade of IL1 
synthesis prevents the beneficial effects observed in FAAH-lacking mice in 
terms of cytokine expression, amyloid deposition, and behavior.  
 
Firstly, we found that FAAH-lacking mice exhibited a significantly higher M1/M2 
ratio of microglial cells as compared to their WT counterparts. This observation 
is in agreement with previous data from our group [7,21] and from others [20] 
and confirm the exacerbated inflammatory state derived of the genetic 
inactivation of FAAH. Furthermore, microglial cells were found to be significantly 
less abundant in the brains of 5xFAD/FAAH-/- mice than in 5xFAD mice. This 
decreased microgliosis was quantified by flow cytometry and confirms our 
previous observation by means of Iba1+ cell densitometry [7], though is in 
contrast with another paper in which an increased microgliosis in FAAH-lacking 
mice was reported [20]. This paradoxical observation (less number of microglial 
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cells but exacerbated inflammatory M1 phenotype) matches with our previously 
suggested hypothesis that FAAH gene deletion has a profound, long-term effect 
on microglial-mediated neuroinflammation, and that the FAAH-lacking brain has 
a net pro-inflammatory status that is evidenced when an acute as well as 
chronic challenge takes place [7,21]. 
 
Furthermore, we here report changes in the cytokine and amyloid levels of the 
AD-inflammed brain that can be associated to the absence of FAAH activity. 
Thus, while mRNA levels of the pro-inflammatory cytokines IL1 and TNF 
were significantly elevated in FAAH-lacking mice, those of anti-inflammatory 
cytokines were decreased (IL10), or at least not elevated (IL4), as a 
consequence of the amyloid pathology in these mice. These changes were also 
accompanied by modifications in the expression pattern of another element of 
the IL1 system (IL1r). Taken together, these data clearly point out to a pro-
inflammatory milieu in the brains of FAAH-/- mice in the context of AD. It is of 
special relevance to note that IL10 has been recently attributed a critical role in 
amyloid pathology [22–24]. Surprisingly, these reports indicated that increasing 
IL10 levels had a significant negative impact on amyloid pathology in terms of 
behavior, amyloid plaques formation or A phagocytosis [22]; in line with this, 
IL10 deficiency had a significant positive influence on amyloid pathology in 
APP/PS1 mice [23]. These observations allow us to speculate that the relative 
decrease in IL10 mRNA levels in 5xFAD/FAAH-/- mice herein reported may be 
one of the causes of the decreased amyloid pathology observed in these mice.   
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The role of inflammation, and specifically of IL1, in the context of AD is a 
subject of intense debate [25]. Though the classic perspective pointed out to a 
neuroprotective role of the early inflammatory response, and attributed 
deleterious effects to the sustainably increased production of pro-inflammatory 
cytokines [2,26], recent findings have paved the way for new approaches to this 
topic. Elegant studies by Shaftel et al [27] and Matousek et al [28] showed that 
the hippocampal overexpression of IL1 in the brains of APPswe/PS1dE9 mice 
drives a beneficial effect, reflected mainly at the molecular level. Paradoxically, 
the same group reported a COX-1-mediated impairment of memory in this 
paradigm of exacerbated IL1 hippocampal activity [29]. 
 
Our present data show that IL1 mRNA levels were significantly higher in 
5xFAD/FAAH-/- mice while those of the protein remained unaltered, as already 
observed in our previous study [7]. We do not have a plausible explanation for 
this discrepancy, other than differences in the sensitivity of the methods 
employed or the existence of putative post-translational mechanisms that might 
dampen the increase in the expression levels of the cytokine. It is worth to 
mention that IL1 concentration has been shown critical in order to enhance or 
inhibit hippocampal LTP through NMDARs, having an impact on memory 
processing [30]. It can thus be speculated that the increase in mRNA levels 
observed in 5xFAD/FAAH-/- mice could lead to a subtle increase in IL1 protein 
at the synaptic level (though not significant when measured in tissue samples), 
that in turn could enhance LTP in these mice. The putative increase in IL1r 
could also collaborate in this effect. Preliminary data obtained in our laboratory 
 19 
suggest a recovery of LTP in the CA1 region of 5xFAD/FAAH-/- mice as 
compared to 5xFAD mice (Ruiz-Pérez et al, in preparation).     
 
The interaction between the ECS and IL1 has been studied for the last few 
years in in vitro experiments [12] as well as in the context of multiple sclerosis 
[31–33] and point to an intimate interplay between the ECS and the IL1 
transmission system in the CNS. Cannabinoid CB1 and TRPV1 receptors have 
been involved in this interaction that has been mainly observed by 
electrophysiological and behavioral methods. In addition, blockade of 
cannabinoid CB1 receptors was shown to prevent the beneficial effects of 
minocycline in a mouse model of brain edema [34]. Due to the paucity of 
available pharmacological tools capable of modifying the activity of the IL1-
controlled transmission and, more specifically, the inability of current IL1r 
antagonists to cross the BBB when administered systemically, we decided to 
explore the putative consequences of impairing IL1 synthesis by using the 
well-known drug minocycline [35]. This compound is widely used in different 
experimental paradigms because of its neuroprotectant properties; in the 
context of AD, minocycline has been shown to provide neuroprotection, prevent 
A deposition, and improve cognitive functions in mice models of AD [17,36]. 
Importantly, minocycline has been also shown to block the activity of the 
caspase-1, also called IL1-converting enzyme, that plays a key role in the 
process of maturation of this cytokine from its precursor form (pro-IL1) to its 
fully functional, mature, variant (IL1) [16]. Thus, minocycline is capable of 
decreasing the levels of mature IL1. Our data showed that minocycline was 
effective in impairing IL1 synthesis in both 5xFAD and 5xFAD/FAAH-/- mice 
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and that this effect was also accompanied by an improvement in 5xFAD mice 
and a worsening in 5xFAD/FAAH-/- mice in the WM memory test. These 
observations match with previously published data [37] and suggest that mice 
lacking FAAH exhibit an exacerbated sensitivity to minocycline treatment and, 
more importantly, that this impairment is detrimental in the context of AD. 
 
In summary, our present findings corroborate that the genetic deletion of FAAH 
has a pro-inflammatory effect in the brain of a transgenic mouse model of AD 
that, paradoxically, has beneficial consequences. In addition, we describe a 
putative link between IL1 and the ECS in the mediation of these effects. 
Further experiments should unveil the precise role of IL1 signaling in the 
effects triggered by an enhancement of the endocannabinoid tone in the 
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LEGENDS TO FIGURES 
Figure 1: Flow cytometry data reveal the pro-inflammatory status of the FAAH-
lacking microglia cells and a decreased number of these cells as a 
consequence of FAAH gene deletion. Ratio of M1 (defined as 
CD11+CD45lo/CD16/32+) to M2 (defined as CD11+CD45lo/CD206+) in Mean 
Fluorescence Intensity (MFI) units (A) was elevated in 5xFAD mice and 
significantly increased in 5xFAD/FAAH-/- mice. measured by flow cytometry 
analysis. Quantification of microglial cells (B) (expressed as the percentage of 
total singlet cells that are CD11+CD45lo cells) increased significantly in 5xFAD 
mice while this number were significantly lower in the brains of FAAH-lacking 
AD mice. (C) Histogram comparing expression by MFI in microglia 
(CD11+CD45low gate) from mice 5xFAD (red line) or 5xFAD/FAAH-/- (magenta 
line) representative of 5 independent experiments. N=5 mice per group. *p0.05 
(2-way ANOVA followed by Bonferroni’s post hoc test). 
 
Figure 2: The genetic deletion of FAAH increases the expression of pro-
inflammatory cytokines while decreases that of anti-inflammatory cytokines in 
the context of AD. IL1 and TNF mRNA levels (A and B) were significantly 
elevated as a consequence of the amyloid pathology; in addition, 5xFAD/FAAH-
/- mice showed an exacerbation in the increased levels in respect to 5xFAD 
mice. The mRNA levels of the anti-inflammatory cytokines IL10 (C) and IL4 (D) 
were differentially regulated, with significant increases in 5xFAD mice but non-
significant in the case of 5xFAD/FAAH-/- mice. Further, IL10 were significantly 
lower in the brains of FAAH-lacking AD mice. A.u. stands for “arbitrary units”. 
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N=8 mice per group. *p0.05 (2-way ANOVA followed by Bonferroni’s post hoc 
test).  
 
Figure 3: Effects of the genetic deletion of FAAH and of the treatment with 
minocycline on several elements of the IL1 signaling system in the context of 
AD. IL1 (A) and IL1r (B) mRNA levels were significantly higher in 
5xFAD/FAAH-/- than in 5xFAD mice. Minocycline treatment decreased mRNA 
levels. IL1ra mRNA levels (C) remained unchanged. (D) The levels of IL1 
protein were significantly decreased by the minocycline treatment. A.u. stands 
for “arbitrary units”. N=8 (A to C) or N=5 (D) mice per group. *p0.05 (2-way 
ANOVA followed by Bonferroni’s post hoc test). 
 
Figure 4: Exposure to minocycline induces opposite effects in AD mice, 
depending on FAAH activity. (A) MWM data reflect a significant improvement in 
5xFAD mice treated with minocycline on day 3 of test while showing a 
significant worsening in memory performance in 5xFAD/FAAH-/- mice on days 3 
and 4. (B) Relative amyloid plaque area was significantly reduced in 5xFAD 
mice and significantly increased in 5xFAD/FAAH-/- mice. Cortical (C) and 
hippocampal (D) soluble amyloid levels were significantly lower in 
5xFAD/FAAH-/- mice and experienced a significant increase as a consequence 
of the treatment with minocycline. A.u. stands for “arbitrary units”. N=8-11 (A) or 
N=5 (B to D) mice per group. *p0.05 (2-way ANOVA followed by Bonferroni’s 
post hoc test). 
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